MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase

Abstract Medulloblastoma is a common embryonic malignant tumor in children. Patients with Group 3 medulloblastoma exhibit the poorest prognosis among all subgroups, and approximately 20% of these patients carry an amplification of MYC. Metabolic reprogramming, a hallmark of cancer, includes the pent...

Full description

Saved in:
Bibliographic Details
Main Authors: Shizun Wang, Dan Zhang, Chunlong Wang, Yuqin Liu
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Acta Neuropathologica Communications
Subjects:
Online Access:https://doi.org/10.1186/s40478-025-02051-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850119325862592512
author Shizun Wang
Dan Zhang
Chunlong Wang
Yuqin Liu
author_facet Shizun Wang
Dan Zhang
Chunlong Wang
Yuqin Liu
author_sort Shizun Wang
collection DOAJ
description Abstract Medulloblastoma is a common embryonic malignant tumor in children. Patients with Group 3 medulloblastoma exhibit the poorest prognosis among all subgroups, and approximately 20% of these patients carry an amplification of MYC. Metabolic reprogramming, a hallmark of cancer, includes the pentose phosphate pathway (PPP) as a branch of glucose metabolism, providing cells with ribose-5-phosphate (R5P) and nicotinamide adenine dinucleotide phosphate (NADPH). The role of PPP in medulloblastoma remains unclear. In this study, we utilized transcriptomic data to identify that high expression of transketolase (TKT) correlates with worse overall survival (OS) in Group 3 patients. We found that TKT promotes proliferation of Group 3 medulloblastoma cell line cells both in vitro and in vivo. Additionally, TKT enhances R5P synthesis, increasing the proportion of S-phase cells and promoting proliferation. TKT also facilitates NADPH synthesis, which reduces intracellular reactive oxygen species (ROS) levels, inhibits ROS-induced cell death, and strengthens cellular resistance to ROS-induced injury. Subsequently, we demonstrated that inhibition of MYC leads to decreased TKT protein levels, and MYC promotes cell proliferation and suppresses cell death via TKT. Chromatin immunoprecipitation-quantitative real-time polymerase chain reaction (ChIP-qPCR) confirmed that employing the antibody targeting MYC enables the immunoprecipitation of DNA localized to the promoter region of TKT. Using luciferase assay and western blot, we verified that MYC and specificity protein 1 (SP1) co-regulate the transcription of TKT and consequently elevates TKT protein levels. Collectively, our study reports that MYC facilitates the proliferation of Group 3 medulloblastoma cells and mitigates ROS-induced damage through TKT, suggesting TKT as a potential therapeutic target for MYC-driven Group 3 medulloblastoma.
format Article
id doaj-art-2a9132f83b8a41f0b06ce7bbcaa4594d
institution OA Journals
issn 2051-5960
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series Acta Neuropathologica Communications
spelling doaj-art-2a9132f83b8a41f0b06ce7bbcaa4594d2025-08-20T02:35:40ZengBMCActa Neuropathologica Communications2051-59602025-06-0113111810.1186/s40478-025-02051-7MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolaseShizun Wang0Dan Zhang1Chunlong Wang2Yuqin Liu3Department of Pathology, Cell Resource Center, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC)Department of Pathology, Cell Resource Center, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC)Department of Pathology, Cell Resource Center, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC)Department of Pathology, Cell Resource Center, Institute of Basic Medical Sciences, School of Basic Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC)Abstract Medulloblastoma is a common embryonic malignant tumor in children. Patients with Group 3 medulloblastoma exhibit the poorest prognosis among all subgroups, and approximately 20% of these patients carry an amplification of MYC. Metabolic reprogramming, a hallmark of cancer, includes the pentose phosphate pathway (PPP) as a branch of glucose metabolism, providing cells with ribose-5-phosphate (R5P) and nicotinamide adenine dinucleotide phosphate (NADPH). The role of PPP in medulloblastoma remains unclear. In this study, we utilized transcriptomic data to identify that high expression of transketolase (TKT) correlates with worse overall survival (OS) in Group 3 patients. We found that TKT promotes proliferation of Group 3 medulloblastoma cell line cells both in vitro and in vivo. Additionally, TKT enhances R5P synthesis, increasing the proportion of S-phase cells and promoting proliferation. TKT also facilitates NADPH synthesis, which reduces intracellular reactive oxygen species (ROS) levels, inhibits ROS-induced cell death, and strengthens cellular resistance to ROS-induced injury. Subsequently, we demonstrated that inhibition of MYC leads to decreased TKT protein levels, and MYC promotes cell proliferation and suppresses cell death via TKT. Chromatin immunoprecipitation-quantitative real-time polymerase chain reaction (ChIP-qPCR) confirmed that employing the antibody targeting MYC enables the immunoprecipitation of DNA localized to the promoter region of TKT. Using luciferase assay and western blot, we verified that MYC and specificity protein 1 (SP1) co-regulate the transcription of TKT and consequently elevates TKT protein levels. Collectively, our study reports that MYC facilitates the proliferation of Group 3 medulloblastoma cells and mitigates ROS-induced damage through TKT, suggesting TKT as a potential therapeutic target for MYC-driven Group 3 medulloblastoma.https://doi.org/10.1186/s40478-025-02051-7Group 3 medulloblastomaMYCTKTCell proliferationROS-induced injury
spellingShingle Shizun Wang
Dan Zhang
Chunlong Wang
Yuqin Liu
MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
Acta Neuropathologica Communications
Group 3 medulloblastoma
MYC
TKT
Cell proliferation
ROS-induced injury
title MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
title_full MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
title_fullStr MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
title_full_unstemmed MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
title_short MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase
title_sort myc promotes group 3 medulloblastoma cell proliferation and alleviates ros induced cell death by upregulating transketolase
topic Group 3 medulloblastoma
MYC
TKT
Cell proliferation
ROS-induced injury
url https://doi.org/10.1186/s40478-025-02051-7
work_keys_str_mv AT shizunwang mycpromotesgroup3medulloblastomacellproliferationandalleviatesrosinducedcelldeathbyupregulatingtransketolase
AT danzhang mycpromotesgroup3medulloblastomacellproliferationandalleviatesrosinducedcelldeathbyupregulatingtransketolase
AT chunlongwang mycpromotesgroup3medulloblastomacellproliferationandalleviatesrosinducedcelldeathbyupregulatingtransketolase
AT yuqinliu mycpromotesgroup3medulloblastomacellproliferationandalleviatesrosinducedcelldeathbyupregulatingtransketolase